Comparison of a 22-gauge Franseen-tip needle with a 20-gauge forward-bevel needle for the diagnosis of type 1 autoimmune pancreatitis: a prospective, randomized, controlled, multicenter study (COMPAS study).


Journal

Gastrointestinal endoscopy
ISSN: 1097-6779
Titre abrégé: Gastrointest Endosc
Pays: United States
ID NLM: 0010505

Informations de publication

Date de publication:
02 2020
Historique:
received: 16 06 2019
accepted: 03 10 2019
pubmed: 28 10 2019
medline: 26 1 2021
entrez: 27 10 2019
Statut: ppublish

Résumé

Histologic diagnosis of autoimmune pancreatitis (AIP) using EUS-guided FNA (EUS-FNA) is difficult. To address this issue, new fine-needle biopsy (FNB) needles were recently developed. Here, we prospectively evaluated 2 newly designed EUS-FNB needles for histologic evaluation in patients with type 1 AIP. This was a prospective, randomized, multicenter trial comparing biopsy specimens obtained with a 22-gauge Franseen needle or a 20-gauge forward-bevel needle in patients with suspected type 1 AIP. AIP was diagnosed according to international consensus diagnostic criteria. The primary endpoint was the sensitivity of EUS-FNB needles, and secondary endpoints were the amount of specimen obtained, histology of the pancreas based on evaluation of lymphoplasmacytic sclerosing pancreatitis (LPSP), and contribution of histologic findings to the diagnosis of AIP. One hundred ten patients were randomly assigned to the Franseen group (22-gauge Franseen needle) or the forward-bevel group (20-gauge forward-bevel needle). EUS-FNB sampling was successful in all patients. Nine patients were excluded because of diagnoses other than AIP. Compared with the forward-bevel needle, the Franseen needle obtained a significantly greater number of high-power fields. Of 101 patients, 39 patients (78%) in the Franseen group and 23 patients (45%) in the Forward-bevel group were diagnosed with level 1 or 2 LPSP (P = .001). Thirty-six patients could not be diagnosed with type 1 AIP without EUS-FNB specimen results. The 22-gauge Franseen needle should be routinely used for histologic diagnosis of type 1 AIP. (Clinical trial registration number: UMIN 000027668.).

Sections du résumé

BACKGROUND AND AIMS
Histologic diagnosis of autoimmune pancreatitis (AIP) using EUS-guided FNA (EUS-FNA) is difficult. To address this issue, new fine-needle biopsy (FNB) needles were recently developed. Here, we prospectively evaluated 2 newly designed EUS-FNB needles for histologic evaluation in patients with type 1 AIP.
METHODS
This was a prospective, randomized, multicenter trial comparing biopsy specimens obtained with a 22-gauge Franseen needle or a 20-gauge forward-bevel needle in patients with suspected type 1 AIP. AIP was diagnosed according to international consensus diagnostic criteria. The primary endpoint was the sensitivity of EUS-FNB needles, and secondary endpoints were the amount of specimen obtained, histology of the pancreas based on evaluation of lymphoplasmacytic sclerosing pancreatitis (LPSP), and contribution of histologic findings to the diagnosis of AIP.
RESULTS
One hundred ten patients were randomly assigned to the Franseen group (22-gauge Franseen needle) or the forward-bevel group (20-gauge forward-bevel needle). EUS-FNB sampling was successful in all patients. Nine patients were excluded because of diagnoses other than AIP. Compared with the forward-bevel needle, the Franseen needle obtained a significantly greater number of high-power fields. Of 101 patients, 39 patients (78%) in the Franseen group and 23 patients (45%) in the Forward-bevel group were diagnosed with level 1 or 2 LPSP (P = .001). Thirty-six patients could not be diagnosed with type 1 AIP without EUS-FNB specimen results.
CONCLUSIONS
The 22-gauge Franseen needle should be routinely used for histologic diagnosis of type 1 AIP. (Clinical trial registration number: UMIN 000027668.).

Identifiants

pubmed: 31654634
pii: S0016-5107(19)32381-8
doi: 10.1016/j.gie.2019.10.012
pii:
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

373-381.e2

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Auteurs

Akira Kurita (A)

Department of Gastroenterology and Hepatology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.

Satoru Yasukawa (S)

Department of Pathology, Kyoto Second Red Cross Hospital, Kyoto, Japan.

Yoh Zen (Y)

Institute of Liver Studies, King's College Hospital, Denmark Hill, London, United Kingdom.

Kenichi Yoshimura (K)

Innovative Clinical Research Center, Kanazawa University Hospital, Ishikawa, Japan.

Takeshi Ogura (T)

2nd Department of Internal Medicine, Osaka Medical College, Osaka, Japan.

Eisuke Ozawa (E)

Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki, Japan.

Yoshinobu Okabe (Y)

Division of Gastroenterology, Department of Medicine, Kurume University, Fukuoka, Japan.

Masanori Asada (M)

Department of Gastroenterology and Hepatology, Japanese Red Cross Osaka Hospital, Osaka, Japan.

Hiroko Nebiki (H)

Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan.

Minoru Shigekawa (M)

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan.

Tsukasa Ikeura (T)

The Third Department of Internal Medicine, Kansai Medical University, Osaka, Japan.

Takaaki Eguchi (T)

Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.

Hirotsugu Maruyama (H)

Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.

Toshiharu Ueki (T)

Department of Gastroenterology, Fukuoka University Chikushi Hospital, Fukuoka, Japan.

Masahiro Itonaga (M)

Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.

Shinichi Hashimoto (S)

Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Hideyuki Shiomi (H)

Division of Gastroenterology, Department of Internal Medicine, Graduate School of Medicine, Kobe University, Hyogo, Japan.

Ryuki Minami (R)

Department of Gastroenterology, Tenri Hospital, Nara, Japan.

Noriyuki Hoki (N)

Division of Gastroenterology and Hepatology, Bell Land General Hospital, Sakai, Japan.

Mamoru Takenaka (M)

Departments of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.

Yoshio Itokawa (Y)

Digestive disease Center, Department of Gastroenterology & Hepatology, Kyoto Katsura Hospital, Kyoto, Japan.

Norimitsu Uza (N)

Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Shunpei Hashigo (S)

Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences Kumamoto University, Kumamoto, Japan.

Hiroaki Yasuda (H)

Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.

Ryoji Takada (R)

Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Hideki Kamada (H)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Hirofumi Kawamoto (H)

Department of General Internal Medicine 2, Kawasaki Medical School, Okayama, Japan.

Hiroshi Kawakami (H)

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Ichiro Moriyama (I)

Innovative Cancer Center, Shimane University Hospital, Shimane, Japan.

Koichi Fujita (K)

Department of Gastroenterology, Yodogawa Christian Hospital, Osaka, Japan.

Hisakazu Matsumoto (H)

Department of Gastroenterology and Hepatology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.

Keiji Hanada (K)

Department of Gastroenterology, Onomichi General Hospital, Onomichi, Japan.

Tadamasa Takemura (T)

Graduate School of Applied Informatics, University of Hyogo, Hyogo, Japan.

Shujiro Yazumi (S)

Department of Gastroenterology and Hepatology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH